AlphAIAlphAI — Financial news for AI agents
investing.comOCT 122 min read$PRE

Lucid Capital Markets initiates Prenetics stock with buy rating

Lucid Capital Markets initiated coverage on Prenetics (NASDAQ:PRE) with a Buy rating and $54 price target, citing its valuation and focus on IM8. The company reported a narrower-than-expected Q2 loss and revenue below estimates. StoneX and B.Riley also issued Buy ratings with targets of $40 and $37, respectively. Prenetics is shifting focus to IM8, a supplement brand co-founded with David Beckham.

Original reporting
investing.com
Published Oct 12, 2026, 10:52 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 12, 2026, 11:02 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$PRE
Bullish
high confidence
Mentioned
$PRE
Relevance
6/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$PREBullishMed
01

Why it matters

Analyst initiation and earnings beat provide fresh catalyst for price movement.

02

Market read

New coverage and earnings beat create a short‑term trading opportunity for PRE.

03

What to watch

Potential dilution from $1 bn growth financing and reliance on IM8 product rollout.

Relevance 6/10Novelty 7/10Timing: pre‑market today

Background

Prenetics, a former COVID‑testing company, is rebranding to IM8 and shifting focus to nutritional supplements.

Company-level read

Ticker impact

$PREBullishHigh confidence
Context

Lucid Capital Markets initiated coverage on Prenetics with a Buy rating and a $54 price target, reporting Q2 adjusted EPS beat and revenue miss.

Expected impact

likely upward pressure as investors price in the rating upgrade and earnings beat.

Evidence & confidence

Analyst initiation and better‑than‑expected EPS are fresh primary information that can move the stock immediately.

Market effects

Sector

Positive coverage may lift other consumer‑health and DNA‑testing peers.

Regional

US‑listed biotech/health stocks could see modest gains.

Global

Limited to investors tracking small‑cap health‑tech equities.

Counterpoint

What could challenge this read

Revenue miss and small market cap could limit upside; price target may be optimistic.

Key entities

  • company
    Prenetics

    NASDAQ‑listed DNA‑testing and health‑supplement firm.

  • analyst
    Lucid Capital Markets

    Initiated coverage with a Buy rating and $54 target.

Read at source← All news

Related articles

AUG 26
$PREMed

Prenetics Global Ltd (PRE): Financial results for Q2 2026

Prenetics Global Ltd (PRE) furnished an SEC Form 6-K — earnings release. Prenetics’ IM8 CEO and CFO Purchase $1.0 Million of Shares in the Open Market Following Second Quarter Results Cumulative Personal Investment by Leadership Since November 2025 Reaches Approximately $3.75 Million NEW YORK, N.Y. – Aug. 26, 2026 (GLOBE NEWSWIRE) – Prenetics Global L

SEC EDGAR 6-K2 min
AUG 25
$PREMed

Prenetics (PRE) Q2 2026 Earnings Call Transcript

Prenetics (PRE) reported Q2 2026 revenue of $46.5M, up 29% from Q1 and 3.9x from a year ago, with IM8 contributing $45M. The company raised its full-year revenue guidance to $220M-$230M and initiated 2027 guidance of $400M+. July saw record revenue of $20.9M and a 21% drop in customer acquisition cost. PRE expects Q3 to be its first positive cash flow quarter and plans to launch new products in Q4 and Q1 2027.

yahoo.com2 min
AUG 18
$PREMed

Prenetics Global Q2 Earnings Call Highlights

Prenetics (NASDAQ:PRE) reported preliminary July revenue of $21.4M, including about $20.9M from IM8, and said it reached its highest monthly level. Q2 added 118,000 new IM8 customers (140,000 active subscribers). Q2 gross profit was $30.2M (65% margin); adjusted EBITDA loss was $19M. It expects H2 2026 adjusted EBITDA loss of $8M to $12M and a first positive quarter on an adjusted free-cash-flow basis with a $1B General Catalyst facility.

yahoo.com7 min
AUG 18
$PREHighAI 9/10

Prenetics Global Limited: Prenetics' IM8 Reports Q2 2026 Revenue Growth of 288% YoY; Raises FY 2026 IM8 Revenue Guidance to $220-230 Million; July Was the First Month of Positive Consolidated Adjusted

Prenetics Global (NASDAQ: PRE) reported Q2 2026 revenue of $46.5 million, up about 288% YoY, and IM8 revenue of $45.0 million, up about 359% YoY. Results were within guidance. The company raised FY 2026 total revenue guidance to $220-230 million and initiated FY 2027 IM8 revenue guidance of $400 million+.

finanznachrichten.de6 min
JUL 30
$PREMed

PartnerRe records $447m in first-half net income

PartnerRe reported first-half 2026 net income of $447 million, down from $493 million a year earlier, with operating income of $689 million and annualised operating ROE of 12.6%. Gross premiums written rose to $5.42 billion. Non-life underwriting profit was $396 million with a 85.1% combined ratio. Investment income increased to $491 million, but unrealised losses reduced net investment return.

royalgazette.com4 min